Second Phase 3 trial of ACT-132577 on systolic and diastolic blood pressure in patients with true resistant hypertension i.e. uncontrolled hypertension
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Aprocitentan (Primary)
- Indications Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 04 Dec 2017 According to a Idorsia media release, trial is anticipated to start in 2018.
- 01 Jun 2017 New trial record
- 22 May 2017 According to an Actelion Pharmaceuticals media release, the company will discuss the design of a Phase 3 program with health authorities. If successful the program will provide the basis for registration.